Volume 2.26 | Jul 22

Prostate Cell News 2.26, July 22, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
With a transgenic model of prostate cancer, researchers showed that tumor development was not suppressed by the adaptive immune system, which was associated with heightened TGF-β signaling in T cells from the tumor-draining lymph nodes. [Immunity]

ON140_AldefluorOptimized_645x110
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

A Novel Nuclear Role for the Vav3 Nucleotide Exchange Factor in Androgen Receptor Coactivation in Prostate Cancer
Researchers demonstrate the importance of Vav3 in castration-resistant prostate cancer and define a novel nuclear function of Vav3 in regulating androgen receptor activity. [Oncogene]

Diagnostic and Prognostic Signatures from the Small Non-Coding RNA Transcriptome in Prostate Cancer
To assess the diversity and abundance of small non-coding RNAs in prostate cancer, researchers analyzed the composition of the entire small transcriptome by Illumina/Solexa deep sequencing. [Oncogene]

Different Effects of Corticotrophin-Releasing Hormone and Urocortin 2 on Apoptosis of Prostate Cancer Cells In Vitro
In the present study, the expressions of both CRFR1 and CRFR2 in mouse prostate cancer cell line RM-1 were detected and cellular apoptosis was monitored in the presence of corticotropin-releasing factor or urocortin 2, the CRFR1 and CRFR2 selective agonist, respectively. [J Mol Endocrinol]

Anti-Tumor Effects of Endogenous Prostate Cancer-Specific CD8 T Cells in a Murine T Cell Receptor Transgenic Model
Researchers used a double transgenic model in which mice express CD8 T cells specific for a prostate/prostate cancer antigen to study the response of CD8 T cells to evolving autochronous prostate tumors in TRAMP mice. [Prostate]

Prostate Cancer Targeting Motifs: Expression of ανβ3 , Neurotensin Receptor 1, Prostate Specific Membrane Antigen, and Prostate Stem Cell Antigen in Human Prostate Cancer Cell Lines and Xenografts
Researchers measured the expression differences in receptor signatures among several human prostate cancer cell lines and xenografts as a function of tumorigenicity. [Prostate]

Elevated Physiological Levels of Folic Acid Can Increase In Vitro Growth and Invasiveness of Prostate Cancer Cells
In this study, researchers investigate the effects of different folic acid concentrations on the growth and invasiveness of prostate cancer cell lines. [BJU Int]

Effect of Quinolinyl Acrylate Derivatives on Prostate Cancer In Vitro and In Vivo
In this study, a series of seven new quinolinyl acrylate derivatives were synthesized and evaluated against human prostate cancer cells PC-3 and LNCaP in vitro and in vivo. [Invest New Drugs]

MicroRNAs Can Predict Prostate Cancer Biochemical Relapse and Are Involved in Tumor Progression
Researchers analyzed formalin-fixed and paraffin-embedded tissue samples from 52 primary prostate cancers and normal adjacent tissues obtained after radical prostatectomy. [Int J Oncol]

CLINICAL RESEARCH

A Phase II Study of Patupilone in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Docetaxel: Canadian Urologic Oncology Group Study P07a
The purpose of this study was to determine the clinical activity of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel. [Ann Oncol]

Chronic Prostatitis Does Not Influence Urinary PCA3 Score
Researchers conducted a prospective study to evaluate the effect of chronic prostatitis on the prostate cancer urinary marker PCA3. [Prostate]

Germline BRCA Mutation Does Not Prevent Response to Taxane-Based Therapy for the Treatment of Castration-Resistant Prostate Cancer
The objective of this study is to investigate the relationship between BRCA mutation status and response to taxane-based chemotherapy. [BJU Int]

ON144-FreeTShirt_645x110

INDUSTRY NEWS

Mirna Therapeutics Announces Allowance of Multiple Patents for Therapeutic Use of Tumor Suppressor MicroRNAs
Mirna Therapeutics, Inc. announced that the United States Patent and Trademark Office has allowed multiple patent claims related to the therapeutic application of several tumor suppressor microRNAs. [Mirna Therapeutics Inc., Press Release]

Adamis Prostate Cancer Drug APC-100 Granted a Patent in US
Adamis Pharmaceuticals Corporation announced the technology which constitutes its compound APC-100 was recently granted a patent in the United States (US). [Business Wire]

Aeterna Zentaris Successfully Reached a Key Milestone in the Non-Clinical Development of its Oral Prostate Cancer Vaccine Candidate, AEZS-120
Aeterna Zentaris Inc. announced that it has successfully reached a key milestone in the non-clinical development of its live recombinant prostate cancer vaccine candidate, AEZS-120, for oral administration. [Aeterna Zentaris Inc., Press Release]

Cancer Research UK Invests in Future World-Leading Scientists
Cancer Research UK has given a number of prestigious grants to new investigators who are set to become the eminent cancer scientists of the future. [Cancer Research UK Press Release]

Family Foundation of Business Leader Invests $4.55 Million In Northwest Biotherapeutics for Promising Clinical Trials In the US and Europe
Northwest Biotherapeutics announced a $4.55 million equity investment on June 28, 2011, by The Richard M. Schulze Family Foundation. [Northwest Biotherapeutics Press Release]

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW American Association for Cancer Research: Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy 
November 3-6, 2011 
Orlando, United States

NEW 3rd European Multidisciplinary Meeting on Urological Cancers 
November 4-6, 2011 
Barcelona, Spain

JOB OPPORTUNITIES

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Post-doctoral Position – Molecular Biology of Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Endocrinology of Prostate Cancer (Baylor College of Medicine)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us